Massachusetts General Hospital

Analysis of Cell line drug sensitivity data

• Drug-specific analyses
• Global overview of analyses
• Download analysis files

Genomics of Drug Sensitivity (GDS)The Genomics of Drug Sensitivity (GDS) Project is part of a unique 5-year collaboration between The Cancer Genome Project at the Wellcome Trust Sanger Institute (UK) and the Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center. The Center for Molecular Therapeutics has pioneered the use of high-throughput platforms for examining the relationship between tumor cell genomics and sensitivity to anti-cancer agents. The Cancer Genome Project has led the way in the systematic analysis of cancer genomes to identify genes critical in the development of human cancers. This collaboration will develop and integrate the expertise at both sites toward the goal of identifying cancer biomarkers that can be used to identify genetically defined subsets of patients most likely to respond to targeted therapies.

GDS Announcements Mailing List

Interested in receiving 'Genomics of Drug Sensitivity' (GDS) news and release information? Sign up here

Mass General Cancer Center

Principal Investigator

• Daniel Haber, MD, PhD

Scientific Advisors

• Sridhar Ramaswamy, MD
• Jeffrey Engelman, MD, PhD

Project Leader

• Cyril Benes, PhD

Post Doctoral Research Fellow

• Elena Edelman, PhD

Database Technical Specialist

• Patricia Greninger

Senior Research Assistant

• Randy Milano

Research Assistants

• Angela Tam
• Jesse Stevenson
• Steve Lutz
• Xeni Mitropoulos

Wellcome Trust Sanger Institute

Principal Investigators

• Michael Stratton
• Andy Futreal

Project Leader

• Mathew Garnett

Clinician Scientist

• Ultan McDermott

Postdoctoral Research Fellow

• Sonja Heidorn

Computer Biologists

• Richard Thompson
• Jorge Soares

Senior Research Assistant

• Anne McLaren-Douglas

Research Assistants

• Andrew Barthorpe
• Tatiana Mironenko
• Laura Hirst
• Patrick Brien